- Country profiles
- Data dashboard
- Satellite Pages
- About us
- WHAT'S NEW
The 2016 Political Declaration of the High-level Meeting of the United Nations General Assembly on Antimicrobial Resistance represented a landmark in the world’s commitment to tackling antimicrobial resistance, calling for greater urgency and action in response to its many challenges. In the political declaration, Member States requested the Secretary-General, in consultation with the Food and Agriculture Organization of the United Nations (FAO), the World Organisation for Animal Health (OIE) and the World Health Organization (WHO) to convene an ad hoc interagency coordination group (IACG) co-chaired by the Executive Office of the Secretary-General and the Director-General of WHO to provide practical guidance for approaches needed to ensure sustained, effective global action to address antimicrobial resistance. It also requested the Secretary-General to submit a report for consideration by Member States by the seventy-third session of the General Assembly in 2019 on the implementation of the political declaration and on further developments and recommendations emanating from the IACG, including on options to improve coordination, considering the 2015 Global Action Plan on Antimicrobial Resistance.
WHO estimates that 71 million people worldwide were chronically infected with hepatitis C virus (HCV) in 2017. Globally, 23% of new HCV infections and one in three HCV deaths are attributable to injecting drug use (PWID). HCV is also a major concern for people detained in prisons and other closed settings – available data demonstrate that one in four detainees are HCV positive.
This policy brief highlights the current landscape of country hepatitis policies for harm reduction and HCV testing and treatment in PWID and people in prisons. It aims to capture how governments are translating the WHO Global health sector strategy on viral hepatitis, 2016-2021 into national plans, and provides a summary of the enablers and barriers to HCV testing and treatment in these populations.
The Global Fund to Fight AIDS, TB and Malaria has opened up the opportunity to incorporate tobacco control into TB and HIV grants. In line with the 2030 Agenda, the UNDP Strategic Plan 2018-2021, and UNDP’s HIV, Health and Development Strategy 2016-21: Connecting the Dots, UNDP and the Secretariat of the WHO Framework Convention on Tobacco Control (WHO FCTC) have produced this Issue Brief to inform Global Fund applicants on integrating tobacco cessation into Global Fund HIV and TB grants. The Issue Brief outlines how tobacco consumption worsens TB and HIV outcomes and how the integration of tobacco control could increase health benefits and efficiencies. Key approaches and practical options for such integration are outlined, based on a review of research and case studies.
Keywords: TB, HIV, SDGs, response, tobacco
The DOH Administrative Order No. 2017-0019 or the Policies and Guidelines in the Conduct of Human Immunodeficiency Virus (HIV) Testing Services (HTS) in Health Facilities defines HIV Treatment hubs as a hospital with an organized HIV and AIDS Core Team (HACT) that facilitates in-patient and out-patient prevention, treatment, care and support services to PLHIV including but not limited to antiretroviral therapy, HIV testing services, clinical management, patient monitoring, and other care and support services.
Every child should be given the best chance to start life healthy and free from preventable diseases. Mother-to-Child transmission to HIV, hepatitis B and syphilis can be effectively prevented by immunization, and screening and treatment of pregnant woman.
The Regional Framework for the Triple Elimination of Mother-to-Child Transmission of HIV, Hepatitis B and Syphilis in Asia and the Pacific 2018-2030 suggests a coordinated approach to delivering these interventions using the shared maternal, newborn and child health platform to achieve elimination.
Strong global commitment to end AIDS has driven huge progress. In 2017, around 75% of people living with HIV globally knew their HIV status and 59% of all people living with HIV were accessing treatment.
However, new HIV infections are not declining fast enough and too many people are still dying from AIDS-related illnesses despite the availability of high-quality and effective treatment. And with 36.9 million men, women and children living with HIV around the world, there are more people than ever before living with HIV. A quarter don’t even know that they have the virus.
This is the first time this regimen will be offered as an affordable, generic, fixed-dose combination, which will increase access for millions of people living with HIV in low- and middle-income countries. Below are a set of key messages and questions and answers to guide communications around the announcement and respond to media inquiries.
Keywords: HIV, ART, treatment, medicines, funding
In 2016, the Kingdom of Thailand formally decided to re-allocate responsibility for drug dependence treatment from the Ministry of Justice (MOJ) to the Ministry of Public Health (MOPH) by the end of 2018. The reforms are designed to increase voluntary access to client-centred drug dependence treatment where the MOPH will be expected to develop guidelines, operating standards and monitoring and evaluation indicators to assess performance. Although Thailand’s drug treatment system has raised significant concerns over the past 15 years, this change is intended by the Government to indicate a shift in the overall approach to drug use and dependence to one based on health and human rights.
This paper offers a brief analysis of these two challenges in light of current policies and practices, along with recommendati ons for overcoming them to ensure the implementati on of a drug treatment system that can result in improved health and human rights outcomes for people who use drugs and people dependant on drugs.
Antiretroviral treatment (ART) optimization is a key pillar in the AIDS Free agenda to reach the goal of ensuring 95% of all infants and children have access to lifesaving treatment.
This policy brief outlines key considerations to facilitate effective transition to more clinically appropriate regimens as optimal ARV medicines and dosage forms become available.
Keywords: HIV, ARV, paediatric, treatment, children